The rise of raloxifene and the fall of invasive breast cancer.
Jordan
V Craig
VC
D000368:Aged; D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control*; D003327:Coronary Disease / Q000517:prevention & control; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride